Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
  • A61K9/2846—Poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
  • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F297/00—Macromolecular compounds obtained by successively polymerising different monomer systems using a catalyst of the ionic or coordination type without deactivating the intermediate polymer
  • C08F297/02—Macromolecular compounds obtained by successively polymerising different monomer systems using a catalyst of the ionic or coordination type without deactivating the intermediate polymer using a catalyst of the anionic type
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L51/00—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L51/00—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
  • C08L51/006—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers grafted on to block copolymers containing at least one sequence of polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers

Definitions

• the present invention relates to a novel oral dosage form, preferably pharmaceutical, targeted delivery of active ingredients in the colon.
• the invention relates to novel polymers allowing targeted delivery of active principles to the colon regardless of its pH, due to a specific degradation of these polymers by the colonic flora.
• novel polymers can be used to effect a coating or serve as matrix agents.
• colon is the preferred site for the absorption of peptides, proteins and many other active principles targeting various pathologies located in other parts of the body, including asthma, angina, arthritis. ..
• the first is to provide an outer coating protecting the active ingredient, which resists the acid environment of the stomach and the enzymes of the intestine to reach intact the colon. This coating must then degrade in the colon to release the active ingredients contained in the drug. Since the colon normally has a substantially neutral pH, the known coatings are designed to withstand the acidic pH of the stomach and to dissolve at a neutral pH, so as to release the drug's active ingredient in the colon only.
• Another approach has been to provide multilayer coatings, so that each polymer is successively degraded by the different media encountered after ingestion of the drug, and so that the last layer is degraded in the colon.
• a last pathway studied in the prior art is no longer a galenic transformation, but a chemical modification of the active ingredient (s) so as to obtain compounds called prodrugs, which are not absorbable in the stomach and the intestine. hail.
• These chemical modifications mainly include the formation of azo compounds or the grafting of sugars to steroids. As they pass through the colon, these prodrug compounds are reduced by bacteria and colonic enzymes and thus restore the pharmacologically active principles.
• the object of the invention is to provide novel polymers for targeted delivery of the active ingredients in the colon. These polymers degrade specifically in the colon and remain intact until they reach this level of the digestive tract. As such, they do not degrade in the mouth, in the stomach and in the small intestine.
• these polymers have no toxicity and the by-products resulting from their degradation are not harmful to health.
• the present invention teaches a new specific colonic release polymer intended to protect, until its arrival at the level of the colon, at least one active principle contained in an oral, in particular pharmaceutical, dosage form and to release it specifically. in the colon.
• This polymer remains intact in the first part of the digestive tract, namely the mouth, the esophagus, the stomach and the small intestine, and is degraded in the colon.
• This polymer based on polysaccharide, undergoes enzymatic degradation in contact with the colonic microflora. Such degradation is independent of pH and is always possible because colonic bacteria and enzymes are always present in sufficient amounts in the colon, even in case of pH change.
• the polysaccharides are water-soluble, they dissolve prematurely in the mouth and stomach.
• the polymers according to the invention are sufficiently hydrophobic not to degrade in the mouth and the beginning of the digestive tract.
• the invention is based on a chemical modification of the polysaccharides to make them more hydrophobic.
• the novel polymer according to the invention is a block copolymer, comprising a polysaccharide block intended to be degraded by enzymes and colonic bacteria whatever the pH of the colon, and at least two hydrophobic polyacrylic blocks, grafted to each other. following the others on the polysaccharide block, which allow the polymer to remain intact until its arrival in the colon.
• the polyacrylic blocks of the polymer according to the invention solubilize when the pH is close to 7, allowing faster release of the active principles when the colon has normal pH conditions.
• the polymers according to the invention thus advantageously allow a release of the active principles at the level of the colon by two different mechanisms: firstly a degradation of the polysaccharide block sensitive to colonic bacteria which occurs in all cases and secondly a solubilization neutral pH polyacrylic blocks obtained when the colon is under normal pH conditions.
• the polymers according to the invention can therefore be used "universally" whatever the patient's situation.
• the polymers according to the invention comprise two or three polyacrylic blocks, each of these polyacrylic blocks preferably being a chain of methyl polyacrylate, of polymethyl methacrylate or of polymethacrylic acid.
• block polymers of the invention may be used to carry out a coating of oral, preferably pharmaceutical, dosage forms. They can also serve as matrix agents for producing such oral dosage forms.
• the invention thus provides oral dosage forms, containing at least one active ingredient to be delivered specifically to the colon and containing at least one specific colonic release polymer according to the invention.
• oral dosage forms are, for example, tablets, capsules, granules, microgranules or others.
• the invention also teaches a method of manufacturing such a specific colonic release polymer, wherein the polyacrylic blocks are obtained by the successive addition of different acrylic monomers on the block. polysaccharide during several successive stages of radical polymerization in emulsion.
• Figure 1 is a diagram illustrating the path of a drug according to the invention in the digestive tract of a patient, with release of the active ingredients in the colon; .
• Figure 2 is a schematic sectional view of a tablet coated with a coating based on a polymer according to the invention; .
• Figure 3 is a schematic sectional view of a granule coated with a coating based on a polymer according to the invention;
• Figure 4 is a schematic sectional view of a capsule containing granules each coated with a coating based on a polymer according to the invention
• Figure 5 is a schematic sectional view of a capsule whose outer wall is coated with a coating based on a polymer according to the invention; .
• Figure 6 is a schematic sectional view of a tablet comprising a polymer according to the invention as a matrix agent; .
• Figure 7 is a schematic sectional view of a capsule containing granules comprising a polymer according to the invention as a matrix agent; .
• FIG. 8 corresponds to the general chemical formula of an example of polymer according to the invention; .
• Figure 9 is a schematic block diagram of a polymer according to the invention; .
• Figure 10 corresponds to the reaction scheme for synthesizing an example of polymer according to the invention;
• FIGS. 11 to 16 are graphs illustrating the time release of an active ingredient contained in three series of tablets coated with a polymer-based coating according to the invention and placed in a simulating test medium. in vitro the pathway in the human digestive system.
• the polymer according to the invention can be used to protect any active ingredient of a drug, whether it is in the form of tablets, capsules, granules, microgranules or any other oral dosage form.
• the preferred field of application of the polymer according to the invention is that of medicine and pharmacy. However, its application is not limited to these areas and may concern in particular herbal medicine, homeopathy, dietetics, cosmetology, food, the veterinary field or breeding.
• the polymer according to the invention can be used as soon as a targeted release of active ingredients in the colon is necessary, desirable or interesting irrespective of the nature of the active ingredient or its function.
• Figure 1 there is shown schematically the path of an oral dosage form or drug 1 according to the invention along the digestive tract 2 of a patient.
• the drug 1 After ingestion by the patient, the drug 1 passes successively into the mouth 3, the esophagus 4, the stomach 5, the small intestine 6 and finally the colon 7 of the patient. Its course in the digestive tract is symbolized by the big black arrows 8.
• the drug 1 according to the invention remains intact throughout the first part of the digestive tract, until it reaches the colon 7 where it starts to release the active ingredient (s) 9 it contains .
• the diffusion of the active ingredient 9 has been symbolized by small arrows 10 in broken lines.
• the residence time of the drug 1 in the colon is long and normally between 24 and 72 hours, which advantageously ensures that all of the active ingredient is released into the colon.
• the drug 1 according to the invention may be designed so that the active ingredient is released quickly and in full as soon as entering the colon or for it to release slowly and gradually throughout the course in the colon .
• the drug 1 according to the invention may affect different dosage forms allowing oral intake.
• Several examples of suitable dosage forms have been shown in Figures 2 to 7. Of course, the skilled man can imagine many other without departing from the scope of the present invention.
• the active ingredient 9 has been symbolized schematically by small white circles.
• the drug 1 is in the form of a tablet 11.
• This tablet 11 has been produced conventionally from a mixture of active ingredient 9 and one or more excipients 12, compressed to form the tablet 11.
• the excipient or the excipients 12 are compounds, generally solid and preferably powdery, suitable for the formation of tablets. It may be any pharmacologically acceptable excipient, having the appropriate properties for such use, including one or more matrix agents optionally mixed with other excipients of different nature. Numerous examples of such excipients exist in the prior art, including lactose, microcrystalline cellulose, cellulose derivatives, gums and the like.
• the tablet 11 is coated with a coating 13 formed of a polymer layer according to the invention, which completely covers the outer surface of the tablet 11.
• thickness of this coating 13 is preferably between 1 .mu.m and 1 mm, with a preferred value of between 100 .mu.m and 200 .mu.m.
• the thickness of the coating 13 must, however, remain sufficient to protect the active ingredient as far as the colon by preventing any prior diffusion of the active ingredient through the coating 13.
• the drug 1 may also be in the form of one or more granules 14 or microgranules, as shown in FIG.
• the granule 14 is composed of one or more excipients 12 serving as a support for the active ingredient 9.
• the excipient 12 is this time adapted to the formation of granules 14 and to the technique used for this formation. It can be the same compound or the same mixture of compounds as for the production of tablets 11 or one or more compounds specific to this application.
• the granule 14 can be obtained by several methods widely known to those skilled in the art, some examples of which are given below.
• the excipient 12 such as a matrix agent and the active ingredient 9 may for example simply be mixed before compression forming.
• the active ingredient 9 can also be absorbed and / or adsorbed on crystals or grains of excipient 12.
• a pasty mixture of excipient 12 and active ingredient 9 can be shaped by extrusion, cutting and spheronization of the pieces obtained.
• the granule 14 is then coated on its entire outer surface with a polymer coating 13 according to the invention, protecting the active ingredient 9 into the colon.
• these granules 14 or microgranules can be grouped into capsules 15 in an amount corresponding preferentially to a unit dose of drug 1.
• the capsule 15 is an envelope 16, preferably based on gelatin, formed of two interlocking parts which enclose a number of granules 14.
• these granules 14 may be coated, each individually, a protective coating 13 based on the polymer according to the invention. The granules 14 are then combined into capsules 15 after being coated separately.
• the protective coating 13 based on the polymer according to the invention may cover the outer surface of the envelope 16 constituting the capsule 15 and no longer each granule 14 individually.
• the granules 14 are then simpler and contain only the active ingredient 9 and the excipient (s) 12. In this case, the coating is carried out after the setting capsule.
• the coating 13 contains one or more polymers according to the invention. It may also contain other compounds suitable for producing such a coating 13, especially a plasticizer, an insoluble structural element irrespective of the pH encountered, for example a polymer marketed under the name "Eudragit RS” or “Eudragit RL", serving to stabilize the mechanical properties of the assembly, or a filler, talc or kaolin, for example, which reduces the overall cost of the coating 13 and protects the active ingredients photosensitive thanks to its white coloring, or any other conceivable substance suitable for producing the coating 13.
• a plasticizer an insoluble structural element irrespective of the pH encountered
• a polymer marketed under the name "Eudragit RS" or “Eudragit RL” serving to stabilize the mechanical properties of the assembly
• a filler, talc or kaolin for example, which reduces the overall cost of the coating 13 and protects the active ingredients photosensitive thanks to its white coloring, or any other conceivable substance suitable for producing the coating 13.
• FIGS. 6 and 7 Another embodiment shown in FIGS. 6 and 7 consists in using the polymer according to the invention, no longer as a coating 13, but as a matrix agent.
• a polymer according to the invention can thus serve as an excipient 12 and more precisely a matrix agent for producing tablets 11 (FIG. 6), granules 14 (FIG. 7) or microgranules isolated or grouped into capsules 15, or any other suitable oral dosage form.
• the polymer according to the invention may be used alone or as a mixture with other matrix agents or excipients used in the pharmaceutical field.
• a mixture of several polymers according to the invention can also be used.
• a peripheral coating is no longer necessary to ensure its protection.
• Such a coating can still be envisaged, whether based on the polymer according to the invention or any other constituent.
• the invention teaches a novel polymer which is a block copolymer, that is to say a polymer having several different polymer chains connected to each other by covalent bonds.
• this copolymer consists of a polysaccharide block 17 and of several polyacrylic synthetic blocks 18.
• the polysaccharide block 17 which is water-soluble in the isolated state, is specifically degraded by colonic enzymes and bacteria in a pH-independent manner.
• This block 17 is made from a polysaccharide macromolecule, preferably dextran, guar gum, amylose, starch, chitosan, pectin or any other molecule comprising sugars and having the property of easily and specifically degraded by enzymes and colonic bacteria.
• the polysaccharide block 17 is formed from dextran.
• Polysaccharides are non-toxic macromolecules consisting of metabolites that are found naturally in the colon. They pose no problem of toxicity, either whole or in the decomposed state.
• the polymer according to the invention also comprises polyacrylic blocks 18 which are grafted onto the polysaccharide block 17 and whose hydrophobic nature advantageously prevents the dissolution of the polysaccharide block in an aqueous medium.
• the polymer according to the invention is sufficiently hydrophobic as a whole not to dissolve too rapidly in aqueous media and to avoid premature release of the active ingredient in the mouth, esophagus stomach or first parts of the intestine.
• polyacrylic blocks 18 solubilize at neutral pH thus allowing a faster release of the active ingredient of the drug protected by the polymer of the invention when the colon is in normal pH conditions.
• Acrylic polymers have long been used in the pharmaceutical field and are known to be non-toxic. Thus, the polymer of the invention as a whole, whole or after decomposition, is absolutely not toxic to the patient.
• the polyacrylic blocks 18 are preferably obtained by successive radical polymerization of acrylic monomers on the polysaccharide block 17.
• acrylic monomers can be added successively to the polysaccharide block by radical route, as shown in FIG. 10.
• These acrylic monomers are preferably chosen from the following group: methyl acrylate, methyl methacrylate and methacrylic acid.
• these monomers must be added successively and not in mixture.
• a relative order of these monomers with respect to each other must also be respected.
• These monomers must thus be added in the following relative order: methyl acrylate, methyl methacrylate and methacrylic acid.
• polysaccharide block 17 a first block 19 formed of a polyacrylate chain of methyl, a second block 20 formed of a polymethacrylate chain. methyl and a third block 21 formed of a polymethacrylic acid chain.
• the last block 21 improves the enzymatic and bacterial degradation of the polysaccharide block.
• the polymethacrylic acid is ionized at pH 7 and contributes to hydrate the polymer more easily, giving it a hydrogel consistency that facilitates the subsequent degradation of the polysaccharide portion by enzymes and colonic bacteria.
• the synthetic part of the copolymer must be composed of several different polyacrylic chains, preferably two or three.
• the synthetic part comprises three polyacrylic chains formed by three successive polymerizations of different acrylic monomers.
• This number may vary, but if it is too high, the steric hindrance may be too great for the enzymes and bacteria of the colon to reach the polysaccharide block to degrade it. Conversely, if this number is too small, the hydrophobicity of the resulting copolymer may be insufficient.
• Polymers according to the invention with two polyacrylic blocks 18 have also been synthesized.
• they may comprise, after their polysaccharide block 17, a block of methyl polyacrylate 19 and a block of polymethyl methacrylate 20, or a block of polyacrylate of methyl 19 and a block of polymethacrylic acid 21, or a block of polymethyl methacrylate 20 and a block of polymethacrylic acid 21.
• the synthesis method used preferably consists of opening a sugar from the polysaccharide block and adding thereto successively the polyacrylic chains one after the other by means of several successive stages of radical polymerization. emulsion.
• a very acid medium 1 obtained by adding nitric acid.
• the concentration of cerium (IV) is preferably between 0.001 and 0.02 mol / l, with a preferential value substantially equal to 0.016 mol / l.
• a sugar of the polysaccharide block is opened and a first polyacrylic acid chain of methyl polyacrylate 19 is fixed by radical polymerization of the methyl acrylate monomers.
• a new polymethyl methacrylate polyacrylic chain 20 is added, which is grafted following the first, by reacting the intermediate compound obtained in step previous with methyl methacrylate.
• the final product is then purified, in particular to remove cerium and unreacted monomers.
• the solution obtained is inserted into a dialysis membrane, which allows the polymer to be separated from unreacted monomers. Likewise, the cerium in solution is removed during this purification.
• the resulting polymer is in the form of a powder.
• this powder is, for example, solubilized or suspended in a conventional pharmaceutical solvent, for example tetrahydrofuran, methanol or ethanol. It can then be sprayed on the drug 1, alone or added in particular with a plasticizer such as by for example, ethyl citrate, butyl phthalate or another polymer, to effect a coating 13.
• a conventional pharmaceutical solvent for example tetrahydrofuran, methanol or ethanol.
• a plasticizer such as by for example, ethyl citrate, butyl phthalate or another polymer, to effect a coating 13.
• the resulting product was purified by dialysis and then lyophilized to obtain the polymer according to the invention.
• the resulting product was purified by dialysis and then lyophilized to obtain the polymer according to the invention.
• amylose corn starch
• a 250 ml three-neck flask equipped with a condenser and stirrer, with argon bubbling was dissolved in 32 ml of 0.2 M nitric acid in a 250 ml three-neck flask equipped with a condenser and stirrer, with argon bubbling. , the balloon being immersed in a water bath at 60 ° C.
• the resulting product was purified by dialysis and then lyophilized to obtain the polymer according to the invention.
• amylose corn starch
• chitosan 70 2.2 g were dissolved in 32 ml of 0.02 M nitric acid in a 250 ml three-neck flask equipped with a condenser and an agitator, with argon bubbling, the flask being immersed in a water bath at 60 ° C.
• the resulting product was purified by dialysis and then lyophilized to obtain the polymer according to the invention.
• chitosan 70 2.2 g were dissolved in 32 ml of 0.02 M nitric acid in a 250 ml three-neck flask equipped with a condenser and an agitator, with argon bubbling, the flask being immersed in a water bath at 60 ° C.
• the inventors have prepared tablets containing theophylline as active ingredient and coated them with different block copolymers according to the invention. They then studied the in vitro release of the active principle contained in the galenic forms thus obtained, all along the path in the simulated digestive system.
• the tablets tested were conventionally obtained by wet granulation from theophylline and a set of excipients, according to a composition detailed in the following table:
• the mixture was then compressed to obtain tablets which were determined to have the following characteristics: mass uniformity, hardness, disintegration behavior, friability and theophylline content.
• the measurements were carried out with reference to the European Pharmacopoeia 6 th edition, 2007. The results obtained are summarized in the table below. These are average values.
• the tablets obtained were then coated with a coating containing a block copolymer according to the invention.
• three coating dispersions were prepared from three different copolymers.
• the first dispersion, called coating 1 contains a copolymer of dextran 70-methyl polyacrylate-polymethyl methacrylate-polymethacrylic acid;
• the second dispersion, called coating 2 contains a copolymer of dextran 70-methyl polyacrylate-polymethacrylic acid;
• the third dispersion, called coating 3 contains a copolymer of dextran 10-methyl polyacrylate-polymethylmethacrylate-polymethacrylic acid.
• the composition of these three coating dispersions is detailed in the following table:
• the tablets were coated with one of these three coating dispersions by spraying with a fluidized air bed. They were then dried in hot air and then parboiled. At the end of the coating process, the inventors obtained three groups of different tablets according to their coating. Compared with the initial uncoated tablets, the coated tablets had a mean weight gain of 10%, respectively, for the coated tablets 1 based on dextran 70 - methyl polyacrylate - polymethyl methacrylate - polymethacrylic acid, at 8, 6% for coated tablets 2 based on dextran 70 - polymethylacrylate - polymethacrylic acid, and 11% for coated tablets 3 based on dextran 10 - methyl polyacrylate - polymethyl methacrylate - acid polymethacrylic.
• phase I to IV the test medium successively simulated gastric fluid (simulated gastric fluid LGS), duodenal fluid (duodenal fluid simulated LDS), fluid intestinal (simulated intestinal fluid LIS) and colonic fluid (simulated colonic fluid LCS).
• FIGS. 11 and 12 show the average quantity of theophylline released as a function of time by the coating tablets 1, in FIGS. 13 and 14 by the coating tablets 2 and in FIGS. 15 and 16 by the coating tablets 3.
• phase IV When the tablets arrive at the colon (phase IV), there is a rapid increase in theophylline release, which continues throughout the course of the tablets in the colon and results in very large amounts of theophylline released at the end. 24 hours, greater than 70% in the presence of dextranase, and even of the order of 80% with the coating 2 or 3 or greater than 90% with the coating 1 in the presence of dextranase and when the colic medium is at a normal pH of 7.2.
• the release of the active ingredient occurs when the pH of the medium is substantially neutral, which corresponds to the normal pH of the colon, by dissolving the polyacrylic blocks even in the absence of enzyme.
• this release is greatly improved in the presence of enzymes, such as dextranase, produced by the colonic microflora, which also make it possible to dissolve the polypeptide block of the polymer according to the invention.
• the polymer according to the invention is therefore more effective than a polymer with a purely acrylic structure when the colon is in normal pH conditions.
• the tested polymer-based coatings according to the invention perfectly fulfill their functions: They protect the active ingredient up to the colon and cause an almost total release of this active ingredient once arrived in the colon, that the colon is at a substantially neutral pH or even at acidic pH.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Polymers & Plastics (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Inorganic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40260849

Family Applications (1)

Country Status (4)

Families Citing this family (3)

Family Cites Families (3)

• 2008
  • 2008-06-12 FR FR0803292A patent/FR2932485A1/fr active Pending
• 2009
  • 2009-06-11 US US12/997,743 patent/US20110189242A1/en not_active Abandoned
  • 2009-06-11 WO PCT/FR2009/000706 patent/WO2009153447A1/fr active Application Filing
  • 2009-06-11 EP EP09766009A patent/EP2294099A1/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events